Jaguar Health, Inc. Announces Reverse Stock Split
Reverse split approved at November 2026 Special Meeting of StockholdersShares of Jaguar Health common stock to begin
Reverse split approved at November 2026 Special Meeting of StockholdersShares of Jaguar Health common stock to begin
Jaguar's rare disease intestinal failure development program for microvillus inclusion disease (MVID) and short bowel
Company plans to file its Earnings Report on November 16, 2026 on Form 10-Q for the quarter ended September 30, 2026
SAN FRANCISCO, CA / ACCESS Newswire / November 6, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company")
Company remains sharply focused on its ongoing rare disease intestinal failure global development program for
Mutation of the GUCY2C gene is the third IF-related congenital enteropathy, in addition to microvillus inclusion
Dividend intended to provide dilution protection to Jaguar shareholders as company continues evaluation of strategic
Company remains sharply focused on its ongoing rare disease intestinal failure global development program for SBS-IF
Dividend intended to provide dilution protection to Jaguar shareholders as company continues evaluation of strategic
Company remains sharply focused on its ongoing rare disease intestinal failure global development program for
Dividend intended to provide dilution protection to Jaguar shareholders as company continues evaluation of strategic
Company remains sharply focused on its ongoing rare disease intestinal failure global development program for
